Table 1.
Patients | 50,000 |
| |
Maximum treatment period with belimumab | 10 years |
| |
Maximum effect related to belimumab | Lifetime |
| |
Subgroup | Patient with low complement and anti-dsDNA |
| |
Responder rule | Reduction SELENA-SLEDAI ≥ 4 at 24th week |
| |
Natural history model | JH-AMS∗ forced in, involvement removed |
| |
Long term disease activity model | Adjusted natural history models (NHM) |
| |
One-year steroid model | NHM |
∗Johns Hopkins University (JH) Adjusted Mean SLEDAI (AMS).